

# Arturo Cesaro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9305093/publications.pdf>

Version: 2024-02-01

63  
papers

1,196  
citations

377584

21  
h-index

466096

32  
g-index

67  
all docs

67  
docs citations

67  
times ranked

1806  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Diagnosis and Management of Cardiovascular Involvement in Fabry Disease. <i>Heart Failure Clinics</i> , 2022, 18, 39-49.   | 1.0 | 18        |
| 2  | The Biological Role of Vitamins in Athletes' Muscle, Heart and Microbiota. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1249.  | 1.2 | 27        |
| 3  | Diagnosis of Fabry Disease in a Patient with a Surgically Repaired Congenital Heart Defect: When Clinical History and Genetics Make the Difference. <i>Neurology International</i> , 2022, 12, 102-108.  | 0.2 | 1         |
| 4  | Early-onset MINOCA: Prognostic implications and considerations for practice. <i>International Journal of Cardiology</i> , 2022, 354, 14-16.  | 0.8 | 1         |
| 5  | Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan-European retrospective observational study. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 832-841.                                      | 0.8 | 23        |
| 6  | Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical Implications. <i>Current Vascular Pharmacology</i> , 2022, 20, 318-320.   | 0.8 | 0         |
| 7  | Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. <i>Cardiovascular Diabetology</i> , 2022, 21, 77.    | 2.7 | 76        |
| 8  | The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review. <i>Inflammopharmacology</i> , 2022, 30, 1143-1151.   | 1.9 | 4         |
| 9  | Risk Scores of Bleeding Complications in Patients on Dual Antiplatelet Therapy: How to Optimize Identification of Patients at Risk of Bleeding after Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2022, 11, 3574. | 1.0 | 2         |
| 10 | Potential role of imaging markers in predicting future disease expression of arrhythmogenic cardiomyopathy. <i>Future Cardiology</i> , 2021, 17, 647-654.  | 0.5 | 8         |
| 11 | Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry. <i>Internal and Emergency Medicine</i> , 2021, 16, 379-387.                  | 1.0 | 21        |
| 12 | Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: from the START Antiplatelet registry. <i>International Journal of Cardiology</i> , 2021, 327, 176-182.                    | 0.8 | 10        |
| 13 | Rheumatic mitral stenosis in a 28-week pregnant woman treated by mitral valvuloplasty guided by low dose of radiation: a case report and brief overview. <i>General Thoracic and Cardiovascular Surgery</i> , 2021, 69, 364-366.               | 0.4 | 0         |
| 14 | Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 904.                                  | 1.2 | 32        |
| 15 | Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1583-1591.   | 1.0 | 9         |
| 16 | Impact of Regular Physical Activity on Aortic Diameter Progression in Paediatric Patients with Bicuspid Aortic Valve. <i>Pediatric Cardiology</i> , 2021, 42, 1133-1140.   | 0.6 | 9         |
| 17 | Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target. <i>Monaldi Archives for Chest Disease</i> , 2021, 91, .  | 0.3 | 0         |
| 18 | Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5863.  | 1.8 | 48        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | SARS-COV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction. <i>Critical Care</i> , 2021, 25, 217.   | 2.5 | 35        |
| 20 | Does a strict glyceimic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108959.  | 1.1 | 42        |
| 21 | Multimodality evaluation of cardiac injury in COVID-19: Getting to the heart of the matter. <i>International Journal of Cardiology</i> , 2021, 339, 243-245.   | 0.8 | 2         |
| 22 | Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 381.                                     | 1.2 | 12        |
| 23 | Advanced Heart Failure in Special Populationâ€”Pediatric Age. <i>Heart Failure Clinics</i> , 2021, 17, 673-683.  | 1.0 | 6         |
| 24 | Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. <i>Reviews in Cardiovascular Medicine</i> , 2021, 22, 755.  | 0.5 | 45        |
| 25 | Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 151-161.  | 0.6 | 53        |
| 26 | Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. <i>International Journal of Cardiology</i> , 2021, 345, 7-13. | 0.8 | 35        |
| 27 | Antithrombotic Therapy in Patients Undergoing Transcatheter Interventions for Structural Heart Disease. <i>Circulation</i> , 2021, 144, 1323-1343.   | 1.6 | 35        |
| 28 | New Frontiers in the Treatment of Homozygous Familial Hypercholesterolemia. <i>Heart Failure Clinics</i> , 2021, 18, 177-188.  | 1.0 | 14        |
| 29 | Coronary stent thickness: thinner is (always) better for all lesions?. <i>Journal of Cardiovascular Medicine</i> , 2021, 22, 26-28.  | 0.6 | 1         |
| 30 | Multidisciplinary In-Depth Investigation in a Young Athlete Suffering from Syncope Caused by Myocardial Bridge. <i>Diagnostics</i> , 2021, 11, 2144.   | 1.3 | 11        |
| 31 | 596<i>â€f</i>Multidisciplinary in-depth investigation in a young athlete suffering from syncope caused by myocardial bridge. <i>European Heart Journal Supplements</i> , 2021, 23, .   | 0.0 | 0         |
| 32 | 760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry. <i>European Heart Journal Supplements</i> , 2021, 23, .                             | 0.0 | 0         |
| 33 | 341 Observational multicentre study on effectiveness and tolerability of Alirocumab in real world, the OMERO study: interim data from the first 699 patients. <i>European Heart Journal Supplements</i> , 2021, 23, .  | 0.0 | 0         |
| 34 | 785â€fSodiumâ€“glucose cotransporter 2 inhibitors in real-life patients at high cardiovascular risk. <i>European Heart Journal Supplements</i> , 2021, 23, .   | 0.0 | 0         |
| 35 | Impact of PCSK9 inhibitors on the quality of life of patients at high cardiovascular risk. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 556-558.   | 0.8 | 39        |
| 36 | Prevalence and clinical implications of hyperhomocysteinaemia in patients with hypertrophic cardiomyopathy and MTHFR C677T polymorphism. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1906-1908.   | 0.8 | 16        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Childhood obesity: an overview of laboratory medicine, exercise and microbiome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1385-1406.   | 1.4 | 11        |
| 38 | Coronary Physiology Assessment for the Diagnosis and Treatment of Coronary Artery Disease. <i>Cardiology Clinics</i> , 2020, 38, 575-588.  | 0.9 | 5         |
| 39 | Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and atrial thrombosis: An appraisal of current evidence. <i>Archives of Cardiovascular Diseases</i> , 2020, 113, 642-651.                        | 0.7 | 9         |
| 40 | Cardiac involvement in systemic sclerosis: "early diagnosis"early management" approach. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1873-1875.  | 0.8 | 1         |
| 41 | Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 76, 173-180.           | 0.8 | 31        |
| 42 | Dietary Thiols: A Potential Supporting Strategy against Oxidative Stress in Heart Failure and Muscular Damage during Sports Activity. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9424.   | 1.2 | 23        |
| 43 | Methicillin-Resistant <i>Staphylococcus aureus</i> : Risk for General Infection and Endocarditis Among Athletes. <i>Antibiotics</i> , 2020, 9, 332.  | 1.5 | 8         |
| 44 | Beyond cholesterol metabolism: The pleiotropic effects of proprotein convertase subtilisin/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition. <i>BioFactors</i> , 2020, 46, 367-380. | 2.6 | 46        |
| 45 | Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Results from the PROGRESS Trial. <i>Current Vascular Pharmacology</i> , 2020, 18, 294-301.  | 0.8 | 8         |
| 46 | How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study. <i>Clinical Cardiology</i> , 2019, 42, 1113-1120.            | 0.7 | 5         |
| 47 | Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). <i>American Journal of Cardiology</i> , 2019, 124, 1662-1668.               | 0.7 | 20        |
| 48 | ECG analysis in patients with acute coronary syndrome undergoing invasive management: rationale and design of the electrocardiography sub-study of the MATRIX trial. <i>Journal of Electrocardiology</i> , 2019, 57, 44-54.        | 0.4 | 7         |
| 49 | Quality Of Life Improvement In High And Very High Cardiovascular Risk Patients Treated With Pcsk9 Inhibitors. <i>Atherosclerosis</i> , 2019, 287, e199.  | 0.4 | 0         |
| 50 | Transradial access versus transfemoral access: a comparison of outcomes and efficacy in reducing hemorrhagic events. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 435-447.   | 0.6 | 24        |
| 51 | Laboratory medicine: health evaluation in elite athletes. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1450-1473.   | 1.4 | 25        |
| 52 | Impact of lipoprotein(a) levels on recurrent cardiovascular events in patients with premature coronary artery disease. <i>Internal and Emergency Medicine</i> , 2019, 14, 621-625.   | 1.0 | 37        |
| 53 | Lomitapide in homozygous familial hypercholesterolemia: cardiology perspective from a single-center experience. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 83-90.   | 0.6 | 13        |
| 54 | Adherence to proprotein convertase subtilisin/kexin 9 inhibitors in high cardiovascular risk patients. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 75-77.  | 0.6 | 34        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Von Willebrand Factor as a Novel Player in Valvular Heart Disease: From Bench to Valve Replacement. <i>Angiology</i> , 2018, 69, 103-112.  | 0.8 | 8         |
| 56 | Functional assessment of coronary stenosis: an overview of available techniques. Is quantitative flow ratio a step to the future?. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 951-962.   | 0.6 | 24        |
| 57 | Lipoprotein(a) screening in patients with premature myocardial infarction: Clinical role and impact on decision-making. <i>Atherosclerosis</i> , 2018, 275, e161.  | 0.4 | 1         |
| 58 | Letter by CalabrÃ² et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)" <i>Circulation</i> , 2018, 138, 218-219. | 1.6 | 0         |
| 59 | Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis. <i>Minerva Cardioangiologica</i> , 2018, 66, 659-670.  | 1.2 | 8         |
| 60 | Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis. <i>Interventional Medicine &amp; Applied Science</i> , 2017, 9, 123-135.   | 0.2 | 2         |
| 61 | Does Accidental Overcorrection of Symptomatic Hyponatremia in Chronic Heart Failure Require Specific Therapeutic Adjustments for Preventing Central Pontine Myelinolysis?. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 266-272.  | 0.6 | 8         |
| 62 | The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. <i>Mediators of Inflammation</i> , 2017, 2017, 1-13.  | 1.4 | 173       |
| 63 | Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis. <i>Journal of Clinical Medicine Research</i> , 2017, 9, 488-498.   | 0.6 | 28        |